跳至主要内容
临床试验/DRKS00025325
DRKS00025325招募中不适用

on-interventional study on Therapeutic Drug Monitoring (TDM) in patients with renal cell carcinoma and on the feasibility of using Volumetric Absorptive Microsampling (VAMS) for sample collection (ON-TARGET) - ON-TARGET

Central European Society for Anticancer Drug Research (CESAR) e.V.0 个研究点目标入组 80 人开始时间: 2021年6月16日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Patients who are being treated with either axitinib or cabozantinib, who have full legal capacity and are linguistically, physically and mentally capable of completing the patient questionnaire independently, and who have provided written informed consent.

排除标准

  • Patients with insufficient knowledge of the German language.

研究者

发起方
Central European Society for Anticancer Drug Research (CESAR) e.V.

相似试验